Clinical trials: Psychoses
Schizophrenia, Schizotypal Disorder
The OPUS YOUNG Trial. Early Intervention Versus Treatment as Usual for Adolescents With First-episode Psychosis
The OPUS YOUNG (OY) study investigates the efficacy of early intervention service versus treatment as usual (TAU) for adolescents aged 12-17 years with a first-episode psychosis.
- Conditions
- Schizophrenia, Schizotypal Disorder, Delusional Disorder, Acute and Transient Psychotic Disorder, Unspecified
- Trial name
- OPUS-YOUNG (NCT04916626)
- Testing
- OPUS YOUNG, Treatment as Usual
- Where
- Denmark
- Volunteers
- 284 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
First Episode Psychosis, Psychosis
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
Psychosis is a disabling condition that typically has its onset in adolescence and early adulthood. Many young people with psychosis have difficulty navigating services or are reluctant to engage in treatment until their illness…
- Conditions
- First Episode Psychosis, Psychosis, Psychotic Episode, Psychoses, Affective
- Trial name
- NCT04298450
- Testing
- Active SMS Intervention
- Where
- Canada
- Volunteers
- 186 people
- Sponsor
- Centre for Addiction and Mental Health
Psychosis, Psychotic Disorders
Imagery Rescripting as a Treatment for Early Psychosis
The goal of this multiple baseline case series study is to test the effect of imagery rescripting (ImRs) in early psychosis. Primary objective :The course of schema or core beliefs, wellbeing and self-esteem in early psychosis.
- Conditions
- Psychosis, Psychotic Disorders, Schizophrenia, Psychoses, Traumatic
- Trial name
- NCT06539780
- Testing
- Imagery Rescripting
- Where
- Netherlands
- Volunteers
- 8 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Schizophreniform Disorder, Bipolar I Disorder
Prevention of Weight Gain in Early Psychoses
The purpose of this study is to determine whether individuals with psychotic spectrum disorders ( Schizophrenia, Schizoaffective disorder,Schizophreniform Disorder, Bipolar Disorder (Type I),Bipolar Disorder (Type II),Major…
- Conditions
- Schizophreniform Disorder, Bipolar I Disorder, Bipolar II Disorder, Major Depressive Disorder
- Trial name
- NCT01075295
- Testing
- Behavioural Intervention for the Prevention of Weight Gain, TAU
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Centre for Addiction and Mental Health
Psychoses, Substance-Induced
Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids
Ketamine, an FDA approved anesthetic agent, is becoming the sedative/analgesic of choice for emergency sedation in children because it causes deep sedation with minimal respiratory depression in comparison to other available…
- Trial name
- NCT00205712
- Testing
- Ketamine, Dexmedetomidine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Schizophrenia, Psychoses
Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis
The study will provide an empirical basis for a pharmacological treatment option. An open-label, randomized, multi-centre parallel group design is used.
- Trial name
- NCT00204061
- Testing
- Supportive management, Amisulpride
- Where
- Germany
- Volunteers
- 124 people
- Sponsor
- University of Cologne
Schizophrenias, Psychoses
Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia
The purpose of this study is to determine whether preventative treatment with sarcosine can reduce symptoms and delay/avoid disease progression in individuals defined as being in a prodromal stage of schizophrenia.
- Conditions
- Schizophrenias, Psychoses, Psychotic Disorders, Schizophrenic Disorders
- Trial name
- NCT00276263
- Testing
- Sarcosine (N-methylglycine)
- Where
- 2 sites in Israel
- Sponsor
- Herzog Hospital
Schizophrenia and Disorders With Psychotic Features, Affective Psychosis, Bipolar
Duration of Untreated Psychosis (DUP) and Pathways to Care in Nordland
During the 1990s, evidence began to emerge of the long duration of untreated illness prior to receiving treatment for patients with psychotic disorders.
- Conditions
- Schizophrenia and Disorders With Psychotic Features, Affective Psychosis, Bipolar, Psychoses
- Trial name
- NCT01196858
- Where
- Norway
- Volunteers
- 62 people
- Sponsor
- University Hospital of North Norway
Diabetes, Hypertension
Pharmacy Interventions to Improve Chronic Disease Medication Refill
Compare the effectiveness of 3 strategies by pharmacists to decrease the time to refill of prescriptions for common chronic diseases (diabetes, hypertension, hyperlipidemia, heart failure, depression, psychoses).
- Conditions
- Diabetes, Hypertension, Hyperlipidemia, Heart Diseases
- Trial name
- NCT00469365
- Testing
- pharmacist contact with the patient via telephone, Pharmacist contact with the patient's physician via fax, Usual care
- Where
- United States
- Volunteers
- 3,048 people
- Sponsor
- Medical University of South Carolina
Psychoses
Access, Detection and Psychological Treatments
Schizophrenia is one of society's most costly medical conditions and the most severe among psychiatric disorders. One of the most important and exciting new concepts in psychiatry is that detection and intervention very early in…
- Trial name
- NCT00260273
- Testing
- Cognitive Behaviour Therapy
- Where
- Canada
- Volunteers
- 56 people
- Sponsor
- Ontario Mental Health Foundation
Psychoses
Brain Cell Injury in Patients With A First Episode of Psychosis
Patients experiencing a first episode of psychosis may have brain cell damage due to a chemical process called oxidation. This study will compare patients with psychosis to healthy volunteers to determine if there are differences…
- Trial name
- NCT00070889
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Hallucinations, Psychoses
Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
The primary objective is to demonstrate that the investigational new drug, ACP-103, is well tolerated by, and will not worsen parkinsonism in, patients with Parkinson's disease and psychosis.
- Conditions
- Hallucinations, Psychoses, Parkinson's Disease
- Trial name
- NCT00087542
- Testing
- ACP-103
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- ACADIA Pharmaceuticals Inc.